Last reviewed · How we verify
NCT04988191
Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer
Status unknown
Phase 1, PHASE2
Last updated 3 August 2021
What this trial tests
Phase 1, PHASE2 trial testing Toripalimab in Colorectal Carcinoma in 44 participants. Status unknown.
Timeline
24 December 2020
Primary endpoint
24 June 2023
24 June 2023
24 December 2023
Quick facts
| Lead sponsor | Peking University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 44 |
| Start date | 24 December 2020 |
| Primary completion | 24 June 2023 |
| Estimated completion | 24 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Toripalimab (TORIPALIMAB) — full drug profile →
- Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
- Irinotecan (irinotecan) — full drug profile →
Conditions studied
- Colorectal Carcinoma — all drugs for Colorectal Carcinoma →
Sponsor
Peking University
Who can join
Adults 18 to 75, any sex, with Colorectal Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a trial investigating the efficacy and safety of Toripalimab combined with bevacizumab and chemotherapy as neoadjuvant therapy in patients with advanced microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR) colorectal cancer.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Unraveling Resistance to Immunotherapy in MSI-High Colorectal Cancer.
Heregger R, Huemer F, Steiner M, Gonzalez-Martinez A, et al · · 2023 · cited 32× · PMID 37894457 · DOI 10.3390/cancers15205090 -
Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers.
Amato M, Franco R, Facchini G, Addeo R, et al · · 2022 · cited 32× · PMID 35955855 · DOI 10.3390/ijms23158726 -
Molecular Landscape and Therapeutic Strategies against Colorectal Cancer.
Patel A, Gulhati P. · · 2024 · cited 7× · PMID 38672633 · DOI 10.3390/cancers16081551 -
Toripalimab, bevacizumab, and irinotecan in dMMR/MSI locally advanced colorectal cancer: First-stage results from a phase 1b/2 trial.
Wang Z, Wang X, Zhang X, Leng J, et al · · 2025 · cited 1× · PMID 40818457 · DOI 10.1016/j.xcrm.2025.102296 -
Case report: Efficacy of immunotherapy as conversion therapy in dMMR/MSI-H colorectal cancer: a case series and review of the literature.
San-Román-Gil M, Martínez-Delfrade I, Albarrán-Fernández V, Guerrero-Serrano P, et al · · 2024 · cited 1× · PMID 38361927 · DOI 10.3389/fimmu.2024.1352262
Verify or expand the search:
- PubMed search for NCT04988191
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Toripalimab
Trials testing the same drug.
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07423078 — Window of Opportunity in Preserving Laryngeal Function Trial · Phase 2 · recruiting
- NCT07480733 — Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors · Phase 2 · not yet recruiting
- NCT07320963 — Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. · Phase 1, PHASE2 · not yet recruiting
- NCT07469956 — Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancre · Phase 2 · not yet recruiting
Other recruiting trials for Colorectal Carcinoma
Currently open trials in the same condition.
- NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
- NCT06557733 — An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis · Phase 2 · recruiting
- NCT07291414 — A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients · NA · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07192068 — Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration · Phase 2 · recruiting
Other Peking University trials
Trials by the same sponsor.
- NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
- NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
- NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
- NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
- NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04988191 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University
- Last refreshed: 3 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04988191.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing